Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 1/20 | 0.33 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL715091 | 0.99 | CCNK (0.32) | CCNKCDK12ADORA3KDM4EMAPK14 | |
| SCHEMBL715092 | 0.99 | CCNK (0.32) | CCNKCDK12ADORA3KDM4EMAPK14 | |
| SCHEMBL3258192 | 0.92 | KDM4E (0.33) | ADORA3KDM4ENPC1CYP1A2CYP3A4 | |
| SCHEMBL710681 | 0.91 | KDM4E (0.32) | ADORA3KDM4ENPC1CYP1A2CYP3A4 | |
| SCHEMBL710680 | 0.91 | PDE4D (0.32) | ADORA3KDM4ENPC1CYP1A2CYP3A4 | |
| SCHEMBL713725 | 0.90 | CYP2C9 (0.38) | CCNKCDK12ADORA3KDM4EMAPK14 | |
| SCHEMBL714072 | 0.89 | CYP2C9 (0.37) | CCNKCDK12ADORA3KDM4EMAPK14 | |
| SCHEMBL714073 | 0.89 | CYP2C9 (0.37) | CCNKCDK12ADORA3KDM4EMAPK14 | |
| SCHEMBL10207830 | 0.82 | CYP2C9 (0.37) | ADORA3KDM4ENPC1CYP1A2CYP3A4 | |
| SCHEMBL10207828 | 0.82 | CYP2C9 (0.39) | ADORA3KDM4ENPC1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124780-B2 | Benzimidazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| EP-1870409-B1 | BENZIMIDAZOLE COMPOUNDS | EISAI R&D MAN CO LTD (JP) | 2010-05-12 | — | — | EP | disclosed |
| US-20090203911-A1 | BENZIMIDAZOLE COMPOUND | MIYAZAWA SHUHEI | 2009-08-13 | — | — | US | disclosed |
| US-7425634-B2 | Benzimidazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| EP-1870409-A1 | BENZIMIDAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-12-26 | — | — | EP | disclosed |
| US-20070015782-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-18 | — | — | US | disclosed |
| US-20070015782-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-18 | — | — | US | disclosed |
| US-20070010542-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-11 | — | — | US | disclosed |
| US-20070010542-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010542-A1 | Benzimidazole compound | HRH2, GIPR, HRH4 | CCNK 3122/4885CDK12 975/4885ADORA3 174/4885 |
| US-20090203911-A1 | BENZIMIDAZOLE COMPOUND | HRH2, HRH4, HRH1 | CCNK 2364/4885CDK12 718/4885ADORA3 488/4885 |
| US-20070015782-A1 | Benzimidazole compound | HRH2, GIPR, HRH4 | CCNK 3122/4885CDK12 975/4885ADORA3 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.